Arlington Heights
Northwest Community Healthcare - (Directions)
800 W Central Rd
Center for Specialty Medicine, LCI
Arlington Heights, IL
Meets: First Monday of each month, 7:00 - 9:00 PM
Contact Debra Panarese for more information.
Phone: 847-253-8866
Email: Arlington Heights
Chicago
Chicago Area Support Group for Individuals Living with Liver Disease - (Directions)
St. Anthony Hospital
2875 W. 19th St.
Chicago, IL 60623
Meets: 2nd Tuesday of Every Month, 2:00 PM - 3:30 PM
Facilitator: Pamela Quinn, BA
Contact Emily Nuzzo for more information.
Phone: 312-377-9030 ext. 12
Email: Chicago
Macon County:
Decatur
Macon County Health Department - (Directions)
1221 E. Condit
Decatur, IL 62521
Meets: Fourth Tuesday of each month, 6:30 - 7:30 PM
Contact Dianna Heyer, RN and Andrea Haubner, RN for more information.
Phone: 217.423.6988 x1320 (217.4236988 x1326)
Homer Glen
Loyola Center for Health at Homer Glen - (Directions)
15750 Marian Drive
Homer Glen, IL 60491
Meets: 6pm, 2nd Thursday of each month
This group begins on November 12, 2009.
Contact Kelly Hofmann, RN, MSED for more information.
Phone: 630-399-5709
Email: Homer Glen
New Beginnings-A support group for individuals living with liver disease
Fairfield, IA
Contact Robert Irno for more information.
Phone: 641-233-0105
Organ Transplant Support Group
Facebook
This site is intended for informational purposes only. The American Liver Foundation (ALF) does not, under any circumstance, engage in the practice of medicine, recommend particular medical professionals or suggest or endorse treatments for specific individuals with liver disease.
Contact: Lisa Beyer
Email: lbeyer002@cfl.rr.com
PBCers
Contact Ivette Williams for more information.
Phone: 773.779.7602
Email: PBCers
Peer to Peer Support Network
Click Here To Visit The Peer To Peer Support Group Website
Contact Emily Nuzzo for more information.
Phone: 312.377.9030 x12
Email: Peer to Peer Support Network
PSC
For additional resources:
www.pscpartners.org
www.psc-support.com
www.psc-literature.org
Contact Becky Long for more information.
Phone: 773-255-0428
Email: PSC
Quad Cities
First Evangelical Lutheran Church - (Directions)
5th Ave. and 13th St
Moline, IL
Meets: Third Tuesday of each month, 6:30 - 8:00 PM
Contact William Bahnks for more information.
Phone: 1-309-762-8193
Rockford
Odd Months: Harlem United Methodist Church/Even Months: Brooke Road United Methodist Church - (Directions)
Odd Months: 8401 North Alpine Road
Even Months: 1404 Brooke Road
Rockford, IL
Meets: Third Thursday of each month, 6:45 - 9:00 PM
Contact Brenda Erwin for more information.
Phone: 815.391.5100
Springfield-"Sangamon Area Hepatitis Support Group"
Springfield Department of Public Health - (Directions)
1415 East Jefferson
Main Floor Conf. Room
Springfield, IL
Meets: Third Monday of each month, 6:00 - 8:00 PM
Contact Don Hunt for more information.
Phone: 217.789.2182
Email: Springfield-"Sangamon Area Hepatitis Support Group"
Winfield (formerly Naperville & Geneva)
Central DuPage Hospital
25 N. Winfield Rd
Meets: First Thursday of each month, 7:00 - 8:30 PM
Contact Kelly Hofmann for more information.
Phone: 630.399.5709
Email: Winfield (formerly Naperville & Geneva)
Acute Liver Failure - Northwestern University
A Multi-Center Trial to Study Acute liver Failure: Data and Specimen Collection Protocol Including Acute Liver Injury (ALI)
To prospectively obtain tissue and blood samples from patients with ALF and encephalopathy and from patients with acute liver injury (ALI). The present study will allow an in-depth analysis of cases of acute liver failure and 40 centers around the United States in the ALF Study Group (ALFSG), with an emphasis on the cause and eventually treatment of this condition.
Requirements
Inclusion Criteria ALF Registry study (and ONAC):
• Between 18 and 70 years of age
• Hepatic illness or jaundice ≤ 26 weeks
• Encephalopathy
• Coagulopathy (INR ≥ 1.5)
Inclusion Criteria ALI Registry study (NO ALI pts are eligible for ONAC. ALI only includes hospitalized patients):
• Acetaminophen (APAP) etiology: acute illness < 2 weeks
*INR ≥ 2.0, ALT ≥ 10X ULN
• NON-Acetaminophen etiology: acute illness < 26 weeks
*INR ≥ 2.0, ALT ≥ 10X ULN, Bili ≥ 3mg/dl
Clinical Trial Investigator: Daniel Ganger, MD
Nurse Coordinator: Jeanne Gottstein
Sponsor: NIH/NIDDK
Last updated 2/26/2009
Contact Jeanne Gottstein for more information.
Phone: 312.908.5902
Acute Liver Failure - Northwestern University
A Multi-Center Trial to Study Acute liver Failure: N-Acetylcysteine (NAC) Open Label Use Study
Following our double blind NAC study for non-APAP ALF, we are now conducting an Open Label study of NAC (ONAC) for this same group. All enrollees must meet criteria for the ALF Registry.
Requirements
Exclusion Criteria for ONAC study:
• Acetaminophen poisoning
• Shock liver
• Malignancy
• Pregnancy
• Severe sepsis
• Cerebral herniation
• Intractable hypotension
• Imminent (≤6 hrs.) death or transplant
Clinical Trial Investigator: Daniel Ganger, MD
Nurse Coordinator: Jeanne Gottstein, 312-908-5902
Sponsor: NIH/NIDDK
Last updated 2/26/2009
Contact Jeanne Gottstein for more information.
Phone: 312-908-5902
Chronic HBV - University of Chicago Medical Center
Single Arm Open Label study to Describe the Antiviral Effect of Entecavir in Africa Americans and Hispanics with Chronic HBV who are Nucleoside/tide-Naïve.
Clinical Trial ID: AI463085
Recruiting patients that are African Americans or Hispanic with Hepatitis B who have not been treated for their liver disease.
CLINICAL TRIAL ELIGIBILITY REQUIREMENTS:
•Inclusion: Aged ≥ 16, Be of African American or Hispanic race, HBV > 24 weeks prior to screening, Nucleoside/tide NAÏVE.
•Exclusion: No current substance abuse, ANC < 1200, Platelet < 70,000, Hgb <10, No IFN treatment ≤ 24 weeks prior to enrollment, no decompensated cirrhosis.
Clinical Trial Investigator: Smruti Mohanty, MD
Nurse Coordinator: Monique L. Williams, RN
Last updated 3/11/2009
Contact Monique L. Williams, RN for more information.
Phone: 773-702-4477
Chronic Liver Disease - University of Chicago Medical Center
“TPL104054, a Randomised, Double-Blind, Placebo Controlled, Multi-Center Study to Evaluate the safety and efficacy of Eltrombopag to Reduce the Need for Platelet Transfusion in Thrombocytopenic Subjects with Chronic Liver Disease Undergoing Elective Invasive Procedures.
Clinical Trial ID: TPL10454
Randomize to 5 treatment plans: 4 treatment plans with drug at different doses: 1mg, 5mg, 10mg, & 40mg. 1 treatment plan with placebo. Patients will be seen at screening (+30days), baseline, treatment day 1, Treatment week 1,2,3,4, and F/U Treatment Week 1,2,3,4.
CLINICAL TRIAL ELIGIBILITY REQUIREMENTS:
•Inclusion: Age ≥ 18 yrs, Childs-Pugh of 12 or less, MELD score of 24 or less, platelet count < 50,000, Na level > 130, Hgb > 8,
•Exclusion: Portal vein thrombosis w/in 3 mths prior to study start, hx of arterial or venous thrombosis, active infection requiring systemic ABX, current, active gr 3-4 bleeding varices, NSAIDS 7 days prior to 1st dose of study meds.
Clinical Trial Investigator: Helen Te, MD
Nurse Coordinator: Monique L. Williams, RN
Last updated 3/11/2009
Contact Monique L. Williams, RN for more information.
Phone: 773-702-4477
EXTRACORPOREAL LIVER ASSIST DEVICE (ELAD®) - University of Chicago Medical Center
SAFETY AND EFFICACY OF THE EXTRACORPOREAL LIVER ASSIST
DEVICE (ELAD®) IN PATIENTS WITH ACUTE ON CHRONIC HEPATITIS (AOCH)
The University of Chicago and Dr. Te are conducting a study to determine the safety and the effectiveness (how well the system works) of a liver assist system. It is designed to provide liver support continuously to subjects with liver failure. The system may potentially treat the sudden worsening of a person with your liver disease. However, it will not treat the chronic liver disease. This system is a dialysis type pump system containing cartridges with filters in them. These filters are made up of hollow tubes that contain human liver cells that have been grown in a laboratory. This system is experimental, which means that it has not been approved by the U.S. Food and Drug Administration (FDA), and it is not an approved for any disease or medical condition
After a subject is screened for study participation, he/she will begin study procedures within 24 hours of your screening visit. He/She will be randomly assigned (like the flip of a coin) to receive either standard medical therapy for liver failure plus the experimental system, or standard medical therapy alone. He/she may participate in this study for up to 70 days.
As part of the study, the subject may undergo the following tests (additional test/procedures may be required): physical exams, blood tests, urine tests, and pregnancy tests.
There is no guarantee that the subject will receive any benefit from taking part in this study. Possible benefits include the subject’s condition remaining the same or improving.
Participation Details:
• Must be between 18 and 70 years of age
• Must have liver failure
• Must be available for clinic visits for the duration of the study
• Must meet study medical criteria as evaluated by Dr. Te
Clinical Trial Investigator: Helen Te, MD
Nurse Coordinator: Sara Rosenkoetter, RN
Last updated 3/4/2009
Email: srosenko@surgery.bsd.uchicago.edu
Contact Sara Rosenkoetter, RN for more information.
Phone: 773-834-9796
HCV Partial Responders - University of Chicago Medical Center
HCV partial responders (2 log drop at TW 12 but not detectable)
5 patients in treatment arms, 5 in placebo arm. Treatment arms patients will have escalating Fluvastatin dose at TW 1,3,5,7,8 (start of HCV standard of care), 10,12,16,20,24,28,32,36,40,44,48,52,56,60,58,80
CLINICAL TRIAL ELIGIBILITY REQUIREMENTS:
•Inclusion: Age 18-65, previous partial responder to attempts at HCV therapy with PEG/RBV (at least 1 log drop but less than 2 log drop in HCV RNA at 12 weeks, Liver biopsy w/n 3 years, compensated liver disease; child pugh class ≤ 6.
•Exclusion: AST or ALT > 10 ULN, Prior intolerance to statin medications, previous side effects to IFN/RBV(psychiatric effect necessitating requiring termination), Neutrophil ≤ 1500, Hgb ≤ 12women or ≤ 13 Men, evidence of illicit drug abuse w/n 1 year.
Clinical Trial Investigator: Guatham Reddy, MD
Nurse Coordinator: Monique L. Williams, RN
Last updated 3/11/2009
Contact Monique L. Williams, RN for more information.
Phone: 773-702-4477
Hepatic Encephalopathy - Rush University Medical Center
Astute Trial
Clinical Trial ID: AST-MHE201
A phase II, multi-center, randomized, double-blind, placebo-controlled, dose ranging trial to evaluate safety and tolerability of an investigational drug for 8 weeks in the treatment of mild Hepatic Encephalopathy.
Clinical Trial Investigator: Nikung Shah, MD
Nurse Coordinator: Doris Yadav, 312-563-3919
Last updated 9/1/2009
Contact Doris Yadav, RN for more information.
Phone: 312-563-3919
Email: Hepatic Encephalopathy - Rush University Medical Center
Hepatitis B - Rush University Medical Center
A Study of Tyzeka in Subjects of Black/African American/Latino Origin, with Compensated Chronic Hepatitis B Virus
Clinical Trial ID: CLDT600 AU506
A 52 week, open-label, single arm multicenter study of Tyzeka (Telbivudine) in nucleoside(+)ide-native subjects of Black/African American and/or Hispanic/Latino origin, with compensated chronic Hepatitis B virus (HBV) infection.
Requirements
- Age 16-70
- Documented compensated chronic Hepatitis B
- Never been treated for Hepatitis B
Clinical Trial Investigator: Nikung Shah, MD
Nurse Coordinator: Doris Yadav, 312-563-3919
Last updated 9/1/2009
Contact Doris Yadav, RN for more information.
Phone: 312-563-3919
Email: Hepatitis B - Rush University Medical Center
Hepatitis B - Rush University Medical Center
Effect of Entecavir in Subjects of Black/African American and Hispanic Origin with Chronic Hepatitis B Virus Infection
Clinical Trial ID: BMS-AI463-085
A study to develop observational clinical experience with the use of Entecavir in patients who are of Black/African American or Hispanic origin and nucleoside/tide naive.
Requirements
- Over 16 years old
- Hepatitis B positive
- Never been treated for Hepatitis B
Clinical Trial Investigator: David VanThiel, MD
Nurse Coordinator: Doris Yadav, 312-563-3919
Last updated 9/1/2009
Contact Doris Yadav, RN for more information.
Phone: 312-563-3919
Email: Hepatitis B - Rush University Medical Center
Hepatitis C - Northwestern University
A Study of SCH 900518 in Previously Untreated Subjects with Genotype 1 Chronic Hepatitis C
Study looking to identify optimal schedule and dosing for SCH 900518 and ritonavir in combination with PegIntron and ribavirin vs. SCH 900518 and ritonavir with 4 week lead-in of PegIntron and ribavirin. This will occur based on undetectable HCV-RNA patients after 4 to 12 weeks of SCH 900518, rate of viral decline, and safety among treatment arms.
Requirements
• HCV treatment naïve
• No HIV/HBV
• No cirrhotic patients
• Liver Biopsy within 2 years
• 18-55 years old
• Genotype 1
Clinical Trial Investigators: Daniel Ganger, MD; Steven Flamm, MD
Nurse Coordinator: Stephanie Rinehart, RN
Last updated 3/2/2009
Contact Stephanie Rinehart for more information.
Phone: 312-503-3580
Hepatitis C - Rush University Medical Center
Enable 2
Clinical Trial ID: TPL108390
Randomized, placebo-controlled, multicenter study to assess the efficacy and safety of Eltrombopag in thrombocytopenia subjects with Hepatitis C virus (HCV) infection who are otherwise eligible to initiate antiviral therapy (Peginterferon Alfa-2a plus Ribaviron).
Requirements:
- Over 18 years old
- Hepatitis C positive
- Platelet count less than 75,000
- No treatment with interferon within the last 30 days.
Clinical Trial Investigator: David VanThiel, MD
Nurse Coordinator: Doris Yadav, 312-563-3919
Last updated 9/1/2009
Contact Doris Yadav, RN for more information.
Phone: 312-563-3919
Email: Hepatitis C - Rush University Medical Center
Hepatitis C - University of Chicago Medical Center
Antiviral effect, safety and pharmacokinetics of once daily BI201335 NA in hepatitis C virus genotype 1 infected treatment-naïve patients for 24 weeks as combination therapy with Pegylated interferon-α 2a and ribavirin (double-blinded randomized, placebo-controlled, Phase II)
Clinical Trial ID: BI 1220.5
The objective of this trial is to investigate antiviral effect, safety and pharmacokinetics of treatment with 120mg or 240mg once daily BI 201335 NA as soft gelatin capsules in HCV genotype 1 infected treatment-naïve patients for 24 weeks in combination with 24 or 48 weeks of Pegylated interferon-α 2a and ribavirin (PegIFN/RBV).
Patients will be randomized to one of 4 treatment arms.
CLINICAL TRIAL ELIGIBILITY REQUIREMENTS:
•Inclusion: age 16-65, diagnosed of HCV for at least 6 months prior to screening, therapy naïve to interferon, HCV viral load ≥ 100,000, liver biopsy w/n 24 months.
•Exclusion: Any mixed genotype, positive HIV-1 or HBV, history of alcohol or drug abuse within the past 12 months, any previous treatment with protease inhibitor, ALT or AST levels 5x ULN.
Clinical Trial Investigator: Donald Jensen, MD
Nurse Coordinator: Monique L. Williams, RN
Last updated 3/11/2009
Contact Monique L. Williams, RN for more information.
Phone: 773-702-4477
Hepatocellular Carcinoma - Northwestern University
A Single-Center Proof of Concept Pilot Study to Evaluate the Safety, Efficacy, and Tolerability of Sorafenib Combined with Therasphere® in Subjects With Hepatocellular Carcinoma Awaiting Liver Transplantation
Clinical Trial ID: Y-90 + Sorafenib STU5761
This is a randomized pilot study for patients with HCC awaiting transplant. Patients will be randomized in a 1:1 fashion to Y-90 alone or in combination with daily sorafenib.
HYPOTHESIS: Subjects treated with sorafenib will have an overall improved response to liver directed therapy with Y-90 (Therasphere) as evidenced by markers of angiogenesis, radiographic response; leading to improved clinical outcome measurements, less recurrence and meeting criteria for liver transplantation.
Requirements:
Inclusion Criteria
•Adults > 18 years old of either gender
•Diagnosis of HCC confirmed by histology or AASLD guidelines o AASLD guidelines of:
•Lesions 1-2 cm evidence of typical vascular pattern on 2 dynamic images OR
•Lesions > 2 cm typical vascular pattern on 1 dynamic image or afp > 200 ng/ml
Exclusion Criteria
•Less than or = 18 years old , „X Ineligible for transplant due to comorbid disease , „X Renal Failure requiring dialysis of any kind
•Evidence of metastatic disease
•Known human immunodeficiency virus (HIV) infection
•Uncontrolled blood pressure (systolic > 160) despite medication(s)
Clinical Trial Investigator: Laura Kulik, MD
Nurse Coordinator: Patrice Al-Saden, RN
Last updated 3/18/2009
Contact Patrice Al-Saden, RN for more information.
Phone: 312-503-1058
Email: Hepatocellular Carcinoma - Northwestern University
NASH - University of Chicago Medical Center
Phase 2, randomized Double blind, placebo controlled study activity of GS-9450 in Adults with NASH
Clinical Trial ID: US-GS-228-0101
Randomize to 5 treatment plans: 4 treatment plans with drug at different doses: 1mg, 5mg, 10mg, & 40mg. 1 treatment plan with placebo. Patients will be seen at screening (+30days), baseline, treatment day 1, Treatment week 1,2,3,4, and F/U Treatment Week 1,2,3,4.
CLINICAL TRIAL ELIGIBILITY REQUIREMENTS:
•Inclusion: Age 18-75, ALT> 60, platelets < 75,000, PT ultrasound, liver biopsy within 12 months.
•Exclusion: cirrhosis, decompensated liver disease, HIV, HBV, HCV, major surgery w/in 1 yr, inflammatory bowel disease, systemic/major illness (CVA, seizure, serious psych disease, pulmonary disease, renal disease), gastric by pass surgeries, substance abuse w/in 1 year.
Clinical Trial Investigator: Nancy Reau, MD
Nurse Coordinator: Monique L. Williams, RN
Last updated 3/11/2009
Contact Monique L. Williams, RN for more information.
Phone: 773-702-4477
Non-Alcoholic Steatohepatitis (NASH) - Northwestern University
A Phase 2, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics and Activity of GS-9450 in Adults with Non-Alcoholic Steatohepatitis (NASH)
Clinical Trial ID: GS-US-228-0101
This study involves an experimental drug names GS-9450, a potential new treatment for preventing liver damage in subjects with NASH. GS-9450 belongs to a group of drugs that block the action of caspases.
The purposes of this research study are (1) to see if 28 days of dosing with different doses of GS-9450 is safe and well-tolerated in patients with NASH, (2) to assess the pharmacokinetics of GS-9450 in humans (see the ‘Pharmacokinetics Testing’ section of the protocol for details), and (3) to assess whether liver problems caused by NASH are improved by taking GS-9450 once per day for 28 days.
Requirements
Non-Alcoholic Steatohepatitis (NASH) Study:
• 18 years or older and NASH
• ALT > 60 U/L
• Fatty Liver on Ultrasound
• Biopsy-proven NASH diagnosed on liver biopsy (within the last 12 months)
• Subjects with type 2 (non-insulin dependent) diabetes for < 10 years that have been stably managed for the last 6 months
• Subjects with stable weight (NO weight loss > 4%) for the past 8 wks
Exclusions Include
• Type 1 Diabetes
• Diabetic peripheral neuropathy, gastoparesis, or duration of type 2 Diabetes ≥ 10 years
Clinical Trial Investigator: Mary Rinella, MD; Steven Flamm, MD
Nurse Coordinator: Jeanne Gottstein, 312-908-5902
Sponsor: Gilead Sciences, Inc.
Last updated 2/26/2009
Contact Jeanne Gottstein for more information.
Phone: 312-908-5902
Print
del.icio.us